新诊断晚期滤泡性淋巴瘤患者R-CHOP治疗后的结局:JCOG0203试验10年随访分析
JCOG0203试验纳入300例初治III/IV期惰性B细胞淋巴瘤(含1-3级滤泡性淋巴瘤)患者,随机接受R-CHOP-21或R-CHOP-14方案。10年无进展生存率两组无显著差异(33% vs 39%,HR 0.89)。10年组织学转化累积发生率9.3%,第二恶性肿瘤累积发生率8.1%。
要点
- R-CHOP-21与R-CHOP-14的10年无进展生存率无显著差异(33% vs 39%,HR 0.89)。
- 10年组织学转化累积发生率为9.3%,第二恶性肿瘤累积发生率为8.1%。
- R-CHOP是新诊断晚期滤泡性淋巴瘤可行的首选治疗方案。
核心结论
- R-CHOP是新诊断晚期滤泡性淋巴瘤可行的首选治疗方案。
- 临床医生在选择一线治疗时应警惕免疫化疗导致的第二恶性肿瘤和感染性疾病严重并发症,两者均可能致死。
研究设计与样本
- JCOG0203是一项2-3期随机试验,纳入日本44家医院中心的初治III或IV期惰性B细胞淋巴瘤患者(包括1-3级滤泡性淋巴瘤)。
- 300例患者按1:1随机分配至R-CHOP-21组(149例)或R-CHOP-14组(151例),R-CHOP-21组排除1例不符合条件者。
- R-CHOP方案:利妥昔单抗375 mg/m2第1天,环磷酰胺750 mg/m2、多柔比星50 mg/m2、长春新碱1.4 mg/m2(上限2.0 mg)第3天静脉给药,口服泼尼松100 mg每日一次第3-7天;每3周(R-CHOP-21)或每2周(R-CHOP-14,需从第8天起每日一次粒细胞集落刺激因子共6天)给药,共6周期,不做利妥昔单抗维持。
- 主要终点:3期部分为无进展生存期,2期部分为完全缓解率;数据截止日期为2017年2月28日。
主要发现
- 10年无进展生存率两组无显著差异:R-CHOP-21组33%(95%CI 25-41)vs R-CHOP-14组39%(95%CI 31-47),HR 0.89(95%CI 0.67-1.17)。
- 248例1-3a级滤泡性淋巴瘤患者中,8年无进展生存率39%(95%CI 33-45),10年36%(95%CI 30-42)。
- 组织学转化累积发生率:5年3.2%(95%CI 1.5-6.0),8年8.5%(95%CI 5.4-12.4),10年9.3%(95%CI 6.1-13.4)。
- 10年第二恶性肿瘤累积发生率为8.1%(95%CI 5.1-12.0),血液学第二恶性肿瘤累积发生率为2.9%(95%CI 1.3-5.5)。
临床怎么用
- 作者认为R-CHOP是新诊断晚期滤泡性淋巴瘤可行的首选治疗选择。
- 作者建议临床医生在选择滤泡性淋巴瘤一线治疗时,应警惕长期随访中免疫化疗导致的第二恶性肿瘤和感染性疾病严重并发症,两者均可能致死。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment for untreated advanced-stage follicular lymphoma is rituximab plus chemotherapy. The incidence of histological transformation of follicular lymphoma has been reported only in heterogeneously treated populations and rarely with long-term follow-up. Additionally, the incidence of secondary malignancies after treatment, without high-dose therapy for follicular lymphoma, is largely unknown. The aim of our study was to assess progression-free survival, overall survival, incidence of secondary malignancies, and incidence of histological transformation in a 10-year follow-up analysis of the JCOG0203 trial. METHODS: In the phase 2-3 randomised JCOG0203 trial, previously untreated patients with stage III or IV indolent B-cell lymphoma, including grades 1-3 follicular lymphoma, from 44 hospital centres in Japan, were randomly assigned (1:1) by use of a minimisation method to receive six cycles of R-CHOP (rituximab [375 mg/m2], given on day 1, plus cyclophosphamide [750 mg/m2], doxorubicin [50 mg/m2], vincristine [1·4 mg/m2, capped at 2·0 mg] given intravenously on day 3, and oral prednisone [100 mg once daily on days 3-7]) every 3 weeks (R-CHOP-21) or every 2 weeks (enabled by mandatory granulocyte-colony stimulating factor administration once daily for 6 days, starting on day 8; R-CHOP-14) without rituximab maintenance. Age, bulky disease (nodal or extranodal mass ≥10 cm in diameter on CT), and institution were used as adjustment factors. Investigators enrolled participants, and assignment to trial groups was done with a computer-assisted randomisation allocation sequence that took place centrally at the Japan Clinical Oncology Group Data Center, without the intervention of investigators. Interventions were not masked for patients or investigators. Data were collected 10 years after enrolment of the last patient. The primary endpoint of the phase 3 part of the study was progression-free survival, and the primary endpoint of the phase 2 part of the study was the proportion of patients who achieved a complete response. Accrual was 4·5 years, and follow-up was 3 years after registration was closed. Data were updated on the cutoff date of Feb 28, 2017. Intention-to-treat analyses (ie, progression-free survival, overall survival, and incidence of secondary malignancies) were predefined, to be done at 10 years after the last patient was enrolled. An additional analysis of the incidence of histological transformation was defined 15 years after the protocol, on May 8, 2017, in a supplementary analysis plan, and assessed at 10 years after the last patient was enrolled. Follow-up is ongoing. This trial is registered with ClinicalTrials.gov, number NCT00147121. FINDINGS: Between Sept 1, 2002, and Feb 28, 2007, 300 patients were enrolled, and 149 (50%) were assigned to the R-CHOP-21 group and 151 (50%) were assigned to the R-CHOP-14 group. After eligibility was assessed, one patient was excluded from the R-CHOP-21 group. 10-year progression-free survival was not different between groups (R-CHOP-21 33%, 95% CI 25-41; R-CHOP-14 39%, 31-47; hazard ratio 0·89, 95% CI 0·67-1·17). In 248 patients with grade 1-3a follicular lymphoma, progression-free survival was 39% (33-45) at 8 years and 36% (30-42) at 10 years. The cumulative incidence of histological transformation was 3·2% (95% CI 1·5-6·0) at 5 years, 8·5% (5·4-12·4) at 8 years, and 9·3% (6·1-13·4) at 10 years after enrolment. At 10 years, the cumulative incidence of secondary malignancies was 8·1% (5·1-12·0) and the cumulative incidence of haematological secondary malignancies was 2·9% (1·3-5·5). INTERPRETATION: R-CHOP is a viable option for first-line treatment in patients with newly diagnosed advanced follicular lymphoma. Clinicians choosing a first-line treatment for patients with follicular lymphoma should be cautious of secondary malignancies caused by immunochemotherapy and severe complications of infectious diseases in the long-term follow-up-both of which could lead to death. FUNDING: National Cancer Center and Ministry of Health, Labour and Welfare of Japan.
引用
- Watanabe T, Tobinai K, Wakabayashi M, et al. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 2018. PMID: 30389034. doi:10.1016/S2352-3026(18)30155-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。